74 studies found for:    Integrin
Show Display Options
Rank Status Study
1 Completed
Has Results
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
Conditions: High-grade Glioma;   Lung Cancer;   Head & Neck Cancer;   Sarcoma;   Melanoma
Intervention: Drug: Fluciclatide Injection - (AH111585 (F18))
2 Terminated
Has Results
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
Condition: Advanced Non-Hematologic Malignancies
Intervention: Drug: PF-04605412
3 Completed The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications
Condition: Genetic Polymorphism
Intervention:
4 Completed Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
Conditions: Melanoma;   Malignant Metastatic Melanoma
Interventions: Biological: MEDI--522;   Biological: Integrin + Dacarbazine
5 Completed
Has Results
The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Biological: BG00002 (natalizumab);   Biological: keyhole limpet hemocyanin (KLH);   Biological: tetanus diphtheria toxoid vaccine (Td)
6 Withdrawn Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: monoclonal antibody anti-anb3 integrin;   Procedure: anti-cytokine therapy;   Procedure: antiangiogenesis therapy;   Procedure: antibody therapy;   Procedure: biological response modifier therapy;   Procedure: growth factor antagonist therapy;   Procedure: monoclonal antibody therapy
7 Active, not recruiting Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis
Conditions: Hypertrophic Cardiomyopathy;   Acute Coronary Syndrome
Intervention: Radiation: 99mTc-NC100692
8 Recruiting Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Conditions: Muscular Dystrophy;   Congenital Muscular Dystrophy;   Fukutin-related Protein Gene;   Limb Girdle;   FKRP Gene;   Childhood Onset LGMD;   Adult Onset LGMD;   POMT1;   POMT2;   POMGnT1;   LARGE;   Alpha Dystroglycan;   Dystroglycanopathy;   Centronuclear;   Multiminicore;   Multicore;   Minicore;   Congenital Fiber Type Disproportion;   Myotubular;   Nemaline;   Congenital Myopathy;   Neuromuscular;   Rigid Spine;   Phenotype-Genotype Correlation;   Cough Assisted Device;   Neuromuscular Disease;   Respiratory Exacerbation;   Invasive Ventilation;   Chest Physiotherapy;   Congenital Myopathies;   Genetic Mutations;   Hypertrophic Cardiomyopathy;   Wheelchair Use;   Cataract;   Opthalmoplegia;   Ullrich Congenital Muscular Dystrophy;   Intermediate Collagen VI Myopathy;   Laminin Alpha 2 Related Congenital Muscular Dystrophy;   MDC1A;   Merosin Deficient Congenital Muscular Dystrophy;   Congenital Muscular Dystrophy Undiagnosed;   Congenital Muscular Dystrophy Merosin Positive;   Walker Warburg Syndrome;   Muscle Eye Brain Disease;   Fukuyama;   Integrin Alpha 7 Deficiency;   Integrin Alpha 9 Deficiency;   Laminopathy;   Lamin AC;   SEPN 1 Related Myopathies;   Bethlem Myopathy;   Dystroglycanopathies;   LGMD2K;   LGMD2I;   LGMD2L;   LGMD2N;   Actin Aggregation Myopathy;   Cap Disease;   Central Core Disease;   Centronuclear Myopathy;   Core Rod Myopathy;   Hyaline Body Myopathy;   Multiminicore Myopathy;   Myotubular Myopathy;   Nemaline Myopathy;   Tubular Aggregate Myopathy;   Zebra Body Disease Myopathy;   Congenital Myopathy Other;   Reducing Body Myopathy;   Sarcotubular Myopathy;   Spheroid Body Myopathy
Intervention:
9 Active, not recruiting A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
Condition: Primary Focal Segmental Glomerulosclerosis
Intervention: Biological: Rituximab
10 Terminated Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)
Conditions: Renal Cell Carcinoma;   Metastases
Intervention: Drug: Volociximab (anti-α5β1 integrin monoclonal antibody)
11 Recruiting 68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma
Condition: Glioma
Intervention: Drug: 68Ga-BNOTA-PRGD2
12 Completed A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
Condition: Multiple Sclerosis
Intervention: Drug: BG00002 (natalizumab)
13 Recruiting PK and PD Study of Natalizumab in Pediatric Subjects With RRMS
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Biological: Natalizumab
14 Terminated Study of Natalizumab in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: BG00002 (Natalizumab)
15 Recruiting Stem Cell Transplant for Epidermolysis Bullosa
Condition: Epidermolysis Bullosa
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Anti-thymocyte globulin;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Procedure: Mesenchymal stem cell transplantation;   Radiation: Total body irradiation;   Procedure: Umbilical cord blood stem cell transplantation
16 Recruiting RGD-PET-CT in Cancer Angiogenesis
Condition: Carcinoma, Renal Cell
Intervention: Drug: 18F-RGD-PET-CT and perfusion CT scans on 3 occasions
17 Not yet recruiting Angiogenesis and Fibrosis in Myocardial Infarction
Conditions: Myocardial Infarction;   Fibrosis;   Neovascularization, Pathologic
Interventions: Procedure: Cardiac MRI scan;   Radiation: CT-PET scan;   Radiation: CT-coronary angiogram
18 Completed
Has Results
Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Condition: Squamous Cell Cancer
Interventions: Drug: Cilengitide 2000 mg once weekly;   Drug: Cilengitide 2000 mg twice weekly;   Drug: Cetuximab;   Drug: 5-fluorouracil (5-FU);   Drug: Cisplatin
19 Completed A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention: Drug: volociximab
20 Active, not recruiting Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cilengitide;   Other: clinical observation;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years